Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The new letter, dated 3 DEC 21, informing MYMD shareholders of the company's past accomplishments, current efforts, and future plans was, in my opinion, brilliantly done! But this provided no support to the company's market performance today. However, in the company's defense, a number of other stocks I follow took a similar drubbing, probably Omicron related.
Speaking of Omicron, on 4 DEC 21, there was a news announcement that the Oravax will initiate testing of its vaccine pill cadidate against Omicron!
https://finance.yahoo.com/news/premas-biotech-oravax-medical-test-130300790.html
This new version of the Covid virus opens a can of worms that will keep the world's labs open 24 hours a day for the next few weeks. They need to demonstrate the effectiveness of the Pfiser, Moderna, J&J and hopefully Oravax's virus pill against the 30 variations of the new Covid virus, before we will know what more needs to be done!
Paul Rivard shot me down pretty quickly with his 15k stock purchase!
Looks like there is sufficient selling pressure to keep MYMD near $6 a share! This is likely to continue until MYMD is able to demonstrate success in reducing TNFa in its life extension study. There is also a possibility that the publication in a scientific journal of the latest rat life extension study by Dr. Caturegli could bring in more MYMD buyers, but probably not enough to overwhelm those who seek to crush MYMD.
WOW !!!!! MYMD feeling increasing downward pressure on increasing volume even after 2 awesome news announcements last Tuesday and Thursday. Looks to me like those who will be seriously hurt by a successful MYMD are trying to kill the beast! Don't believe they will succede because most of our MYMD info now comes from Johns Hopkins!
Has anyone purchased anatabloc recently, and if so, how many bottles did you receive compared to what you paid for!
Fantastic news, but the stock gets crushed!
Have been waiting ever so impatiently for the publication of the latest healthy life extension study done on lab rats led by Dr. Caturegli. All previous such study results have been widely published by the medical media, but ignored by the news media. Perhaps study results that imply potential healthy life extension for all human beings is enough to get the attention of the news media, and they give it wide publicity.
That's all we need to get people looking into the amazing potential of MYMD-1, and learning the story of halting needless inflammation that one Jonnie R. Williams Sr. told us about, over 10 years ago!
Yes, leifsmith, it isn't easy to untangle. My GUESS is that what we now call ORAVAX was a wholly owned subsidiary of MYMD, perhaps not by that name, but was nothing more than the Premas Biotech trivalent vaccine which Akers had ordered from Premas. Then someone got the brilliant idea that making it available as a pill (Oramed), would enhance its value astronomically. Since the pill version is what provides the astronomic value to the vaccine, Oramed ended up owning 87% of the newly formed ORAVAX , and MYMD 13%.
You ask, "Does the extraordinary performance of Oramed in the last year (10x) have an effect on the value of MYMD?"
My answer, "NO"!
Reviewed the last 10Q, and as I expected, there is no mention of Oramed, simply because MYMD has no ownership in Oramed.
Oramed's price performance is based on its pursuit of a pill form of the injectable medication for diabetes, and possibly the pill form of the Premas vaccine for Covid 19.
I am assuming that some viewers here have received the email from MYMD detailing that SEEKING ALPHA had notified its subscribers on Friday before the market opened that MYMD was one of the 3 "breakout" stocks it will release to the public next week. SEEKING ALPHA has a $160.00 target price on MYMD. Also, on Oct. 30, 2021 STOCKS REGISTER released a report on MYMD in which it said analysts have put a 1 year target on MYMD of $1,536.00 based on technical factors only.
MYMD is up .32 @ 9.08 in the aftermarket. Also, 50 Feb. 18, 2022 option contracts to purchase MYMD @ $10.00 traded today @ $1.50.
I have come to the conclusion that MyMD is waiting for the publication of the results of Johns Hopkins' Dr. Caturegli's study on the life extension and maintained muscle strength of mice treated with MYMD-1, before beginning the expected study of humans also to be treated with MYMD-1.
In that study 54 mice, in 3 groups of 18 mice were treated, 1 group with MYMD-1, 1 group w/ rapamycin, and 1 group with rapamycin and metformin, both of which have life extension characteristics. The mice were all treated from the human equivalent age of 58 to 85, at which point all of the 36 mice receiving rapamycin and rapamycin/metformin had died, but a goodly number, (that number not yet released), of the mice receiving MYMD-1 were still alive and strong!
Wall Street's Ray Blanco has dubbed them the "immortal mice", which is unfortunate because they are far from "immortal", and it demeans the seriousness of the results.
The NEWS that Chris Chapman is being recognized by the Arthritis Foundation for his leadership in contributing to a significant advancement in the treatment of arthritis is fantastic news which MYMD took full advantage of in their announcement. The reaction of Wall Street clearly demonstrates they are not on our side!!!
On that list of MyMD personnel scheduled to receive free shares of MYMD on reaching specified levels of net worth, Jonnie R. Williams SR. and JR. are obvious by their absence!
SEAN
Looks to me like the 1 billion market valuation will be reached in a number of MONTHS, (less than 6)!
The flurry of Form 4's posted to the SEC after Friday's close appear to be a notification of the number of shares 8 members of MyMD team would receive should the market capitalization of the company reach the milestones specified in the merger agreement.
Those milestones are $500 million, $750 million, and $1 billion.
Should all of the milestones be reached within the 3 years specified in the agreement, the following MyMD members would receive the following number of shares.
Chapman 600,000
Rivard 200,000
Silverman 600,000
Uzonwanne 150,000
White 150,000
Schreiber 150,000
Kaplin 600,000
Eagle 150,000
Total 2,600,000
They would receive 1/3 of their allotment on reaching the 1st milestone, 1/3 on reaching the 2nd milestone, and the remainder on reaching the 3rd milestone.
Thanks liefsmith.
The following link includes Ray Blanco's discussion about MyMD Pharma starting at around 14 minutes and ending at around 24 minutes! Enjoy!
https://www.facebook.com/100054118495450/videos/1008652009710542/
What's driving this up today on heavy volume!
The MyMD presentation this morning at the Bezinga Conference is available at the following link and begins at about 1;05!
Has this been posted yet from WAINWRIGHT CONFERENCE!
https://journey.ct.events/view/3dcf6a32-1bdd-4df3-8dc9-ec240a6201b0
Has this been posted yet from WAINWRIGHT CONFERENCE!
https://journey.ct.events/view/3dcf6a32-1bdd-4df3-8dc9-ec240a6201b0
Has this been posted yet from WAINWRIGHT CONFERENCE!
https://journey.ct.events/view/3dcf6a32-1bdd-4df3-8dc9-ec240a6201b0
MyMD's 6th Path To Success
This Path relates to the Akers Biosciences / Premas Biotech Covid 19 vaccine!
History - When Akers was an independent company it contracted with Premas Biotech of India for a Covid 19 vaccine, and Premas delivered with a trivalent Covid 19 vaccine. With the merger of MyMD and Akers the vaccine became a part of the new public MyMD Pharmaceuticals Inc. MyMD then joined with Oramed Pharmaceuticals to form Oravax Medical, a company focussed on vaccines in pill form, owned 13% by MyMD and 87% by Oramed, and assigned to it the RIGHTS to the Premas vaccine.
The Covid 19 vaccine developed by Premas is a trivalent vaccine, targeting 3 proteins on the Covid molecule, unlike the Pfizer and Moderna vaccines which target only the "spike" protein. This makes the Premas vaccine a much stronger vaccine against any variants that may develope.
Oravax has since licensed Premas to develope a injectable version of the vaccine for use in India. Sales of the injectable there, and sales of the pill form which is easily shipped anywhere, needs only normal refridgeration, and does not require medical personnel to administer it, would likely be a huge seller producing huge royalties.
MyMD's 5th PAT TO SUCCESS
On Aug. 10, 2021 MyMD announced receipt of patent # 11,085,047,covering its synthetic CBD molecule.
https://www.businesswire.com/news/home/20210810005909/en/MyMD-Pharmaceuticals-Announces-Issuance-of-U.S.-Patent-for-Synthetic-Cannabinoid-Compounds-for-Treating-Neuroinflammatory-and-Neurodegenerative-Diseases
On Sept. 22, 2021 MyMD Pharma issued a press release indicating that SUPERA CBD is 8000 times more effective than plant based CBD in activating health improvement in mammals.
https://finance.yahoo.com/news/mymd-pharmaceuticals-announces-data-demonstrating-150000774.html
With results like this it's hard to see how plant based CBD could any competition for SUPERA CBD.
Best article I've seen on MYMD!
https://biobuzz.io/mymd-takes-on-inflammatory-related-diseases-with-mymd-1/
MyMD Pharma's 4th Path to Success
The following link kind of says it all when it comes to MYMD-1 and and COVID 19.
https://www.businesswire.com/news/home/20210805005659/en/MyMD-Pharmaceuticals%E2%80%99-Lead-Compound-MYMD-1-Shown-to-Suppress-a-Major-Cause-of-Death-in-COVID-19-in-Human-Cell-Study
MyMD Pharma's 3rd Path to Success
In Dec. 2020 MyMD began to review the results of a study led by Dr. Caturegli that looked more deeply into the impact of dosing aging lab animals with MYMD-1. It appears that it supports the previous indication that these subjects live longer and healthier than similar aging subjects not receiving MYMD-1. These study results have been submitted to an appropriate medical journal for peer review and publishing, expected to occur in 2021's 4th quarter.
On Sept. 13 ,2021 MyMD issued a "SIGNAL NEWS RELEASE" which contained the following;
September 13, 2021 10:00 AM Eastern Daylight Time
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. Interim efficacy analysis from this study is expected in the first quarter of 2022."
Should it turn out that MYMD-1 is capable of "extending healthy lifespan", then the market size for this is the 770 million humans over age 64. And, if this isn't enough, it would also be applicable to all other mammals. In this regard, MyMD has already created a corporation called My Vet Pharmaceuticals to handle the "Life Extension" business of non-human mammals.
OOPS, sorry! In both cases last message should have read BILLION, not MILLION.
MyMD Pharma's 2nd path to success
On July 27, 2021 MyMD Pharma released the results of a study conducted by Eurofins Discovery that compared the results of MYMD-1, acting as a JAK inhibitor against 3 popular JAK inhibitors, and found the results to be similar. That means that MYMD-1 could garner its share of this market when it becomes a drug, a market of about 20 million a year, forcasted to grow to 300 million a year by 2026, a growth rate exceeding 50 % a year.
https://www.businesswire.com/news/home/20210727005570/en/MyMD-Pharmaceuticals%E2%80%99-Lead-Compound-MYMD-1-Shows-Commonality-in-Comparative-Study-with-FDA-Approved-Anti-Inflammatory-and-Anti-Autoimmune-Drugs-Used-for-Arthritis-Colitis-and-Dermatitis
JONNIE tried bucking BIG PHARMA with anatabine and got his head handed to him on a platter! Which is why I long ago suggested sharing the seemingly huge market MYMD-1 seems to address (TNF-a, JAK-STAT suppression, Covid-19, anti-aging). By establishing a benefit of MYMD-1 in Phase 2, then licensing that benefit to BIG PHARMA in return for licensing fee, progress payments, drug approval payment, and royalties MyMD passes all the risk off to BIG PHARMA in return for sharing the profits.
That said, MyMD may have a good reason for seeing it differently.
TAKE NOTE ! On the brighter side, 22 MYMD Feb. 18th $10.00 call options were traded at $1.50. Someone was willing to pay $1.50 a share for the right to buy 2200 MYMD shares at $10.00 a share until Feb. 18th.
WOW, WHAT AN AWESOME REACTION TO AWESOME NEWS !!!!!
I had posted some time ago that this would happen, and suggested at the time that it might be better for MYMD to license to a major pharmaceutical company any demonstrated positive phase 2 application in return for license payments, progress payments, and royalties on sales of any new drug approved.
That way BIG PHARMA would be working with MYMD instead of trying to crush it !!!!!
TODAY'S NEWS RELEASE IS AN "IN YOUR FACE", "NO HOLDS BARRED", "TELLING IT LIKE IT IS" BLOCKBUSTER !!!!!
https://ih.advfn.com/stock-market/NASDAQ/mymd-pharmaceuticals-MYMD/stock-news/86036406/mymd-pharmaceuticals-announces-fourth-quarter-2021
FLUSHING OUT MyMD'S PATH # 1 TO SUCCESS
1. MYMD-1 is the 1st 2nd generation TNF-alpha "modulator", which blocks only
the TNF-alpha that exceeds the needs of the innate immune system. All other
TNF-a blockers, including Humira, block all TNF-a, leading to the FDA "black
box" warning that "taking this medication will disable your immune system.
By not blocking the immune system, MYMD-1 has a huge potential competative
advantage over the TNF-alpha blockers.
MyMD Pharma's Paths To Success
1. MYMD develops world's 1st 2nd generation TNF-alpha modulator.
2. Lab comparisons of MYMD-1 with 3 popular JAK STAT blockers finds it
to be equally effective, giving it the opportunity to garner portion
of this market.
3. MyMD expects to offer to all humans over the age of 64 the
opportunity to live longer, and live healthier while doing so. It
also sees the
same benefit to all other mammals who reach comparable ages.
4. Soon MyMD will be dosing patients diagnosed with Covid 19 induced
depression, with MYMD-1, a powerful anti-depressant. While it is
expected to be effective, it will also demonstrate if it is
effective against Covid 19 side effects and "long-hauler" problems.
5. On Aug. 10, 2021 MyMD announced receipt of patent # 11,096,933,
covering its synthetic CBD molecule.
6. AND, if all of the above was not enough, on Aug. 10, 2021 MyMD
announced its ownership of 13% of the stock of Oravax Medical, a
company which has begun the 1st test of a Covid 19 vaccine pill.
The FDA makes another move against some of the JAK inhibitors.
https://www.fiercepharma.com/pharma/pfizer-abbvie-lilly-arthritis-drugs-hit-much-dreaded-fda-heart-safety-cancer-warnings?mkt_tok=Mjk0LU1RRi0wNTYAAAF_QjE-4VIdN-moUa4VgNSeFPg7GXCALa-GkgkH-NQF4nt1aPokbda4xl2T85k4uK2DlkbED8HNFYw23jvbAUfnvvZA9vMSQ-_P6FhXQ8YIBjg5lTQ&mrkid=687556
This market has been forecast to grow from 2020's 18 billion dollars to 300 billion by the end of 2026, a growth rate exceeding 50% a year. Note the following news release from MyMD that indicates that MYMD-1 is comparable to 3 leading JAK inhibitors.
https://www.businesswire.com/news/home/20210727005570/en/MyMD-Pharmaceuticals%E2%80%99-Lead-Compound-MYMD-1-Shows-Commonality-in-Comparative-Study-with-FDA-Approved-Anti-Inflammatory-and-Anti-Autoimmune-Drugs-Used-for-Arthritis-Colitis-and-Dermatitis
MYMD board is blocking my attempts to post my opinion about MyMD PHARMA'S paths to success !